1128P A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma von Patel, S., Mckean, M., Piperno-Neumann, S., Shoushtari, A.N., Hernandez-Aya, L., Orloff, M., Khan, S., Montazeri, K., Kapiteijn, E., Buchbinder, E., Agresta, S., Reilly, S., Patriquin, C.M., Hickman, D., Corrigan, D., Granlund, L., Hentemann, M., Piel, J., Martin, P., Mehmi, I.

Volltext